Table 4C.
Performance of Biolidics in capillary samples of patients with SARS-CoV-2.
| Case ID | Symptom onset, days | Days since PCR diagnosis | Capillary |
||
|---|---|---|---|---|---|
| IgM | IgG | IgM or IgG | |||
| P40 | 19 | 18 | ND | D | D |
| P41 | 31 | 29 | ND | D | D |
| P42 | 31 | 30 | D | D | D |
| P43 | 28 | 25 | D | D | D |
| P44 | 32 | 28 | ND | D | D |
| P45 | 32 | 28 | ND | D | D |
| P46 | N/Aa | 38 | ND | D | D |
| P47 | 36 | 35 | ND | D | D |
| P48 | 48 | 46 | ND | ND | ND |
| P49 | 48 | 45 | ND | D | D |
| P50 | 27 | 26 | D | D | D |
| P51 | 61 | 31 | D | D | D |
| P52 | 33 | 31 | D | D | D |
| P54 | 37 | 36 | D | ND | D |
- D, detected; ND, not detected.
Asymptomatic patient.